Glycation impairs high-density lipoprotein function

Diabetologia. 2000 Mar;43(3):312-20. doi: 10.1007/s001250050049.

Abstract

Aims/hypothesis: To examine the effects of incubation of high-density lipoprotein (HDL) under hyperglycaemic conditions on several functions of HDL in vitro.

Methods: Human HDL (5 mg protein) was incubated for 1 week at 37 degrees C in the presence or absence of 25 mmol/l glucose. Additional samples of human HDL were incubated in butylated hydroxytoluene to control for oxidation.

Results: High-density lipoprotein incubated for 1 week in 25 mmol/l glucose had significant increases in the glycation product, fructoselysine and in the advanced glycation end product, N epsilon-(carboxymethyl)-lysine. High-density lipoprotein apolipoprotein AI and AII concentrations were not altered but glycated HDL had a 65% reduction in paraoxonase enzymatic activity. Glycated HDL did not inhibit monocyte adhesion to human aortic endothelial cells in response to oxidised low-density lipoprotein in vitro (43 +/- 4 monocytes bound vs 21 +/- 2 monocytes for control HDL, p < 0.0001). Hepatic lipase-mediated non-esterified fatty acid release from HDL lipids was enhanced in glycated HDL compared with control HDL (25 +/- 1 vs 16 +/- 1 nmol non-esterified fatty acid hydrolysed/min, respectively, p < 0.0001). Direct glycation of purified paraoxonase protein by incubation in 25 mmol/l glucose caused a 40% reduction in enzymatic activity. This glycated paraoxonase did not inhibit monocyte adhesion to human aortic endothelial cells in vitro (68 +/- 3 monocytes vs 49 +/- 2 monocytes bound for control paraoxonase, respectively, p < 0.001). We also measured a 40% reduction in paraoxonase activity in patients with Type II (non-insulin-dependent) diabetes mellitus and documented coronary artery disease compared with non-diabetic subjects, p < 0.0001.

Conclusions/interpretation: Alterations in function of HDL caused by exposure to hyperglycaemic conditions could contribute to the accelerated atherosclerosis observed in Type II diabetes.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aorta / cytology
  • Aorta / physiology
  • Aryldialkylphosphatase
  • Cell Adhesion / drug effects
  • Diabetes Mellitus, Type 2 / metabolism
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / physiology
  • Esterases / metabolism
  • Esterases / pharmacology
  • Glucose / metabolism*
  • Glycation End Products, Advanced / metabolism
  • Humans
  • Lipase / metabolism
  • Lipid Metabolism
  • Lipoproteins, HDL / metabolism
  • Lipoproteins, HDL / physiology*
  • Lipoproteins, LDL / pharmacology
  • Liver / enzymology
  • Monocytes / physiology
  • Oxidation-Reduction
  • Substrate Specificity

Substances

  • Glycation End Products, Advanced
  • Lipoproteins, HDL
  • Lipoproteins, LDL
  • Esterases
  • Lipase
  • Aryldialkylphosphatase
  • Glucose